Read by QxMD icon Read

Journal of Viral Hepatitis

Zhenqiu Liu, Xingdong Chen, Tiejun Zhang
We thank Dr. Zhao for his interest in our study. Estimation of the incidence of most infectious diseases is challenging, because infection might have occurred several years before symptoms arise or a diagnosis is made. As a result, we used "reporting incidence" rather than "incidence" in our study, which refer to the incidence of hepatitis B virus (HBV) infection derived from a web-based surveillance system. This article is protected by copyright. All rights reserved.
September 21, 2018: Journal of Viral Hepatitis
Juan Macías, Francisco Téllez, Antonio Rivero-Juárez, Rosario Palacios, Luis E Morano, Dolores Merino, Antonio Collado, Lucio García-Fraile, Mohamed Omar, Juan A Pineda
Varicella-zoster virus and hepatitis B virus reactivations have been reported after starting interferon-free direct acting antiviral agent (DAA) combinations. HIV/HCV-coinfected patients could be a high-risk group for the reactivation of latent infections. Because of these, we report the occurrence of severe infections after starting DAA regimens in HIV/HCV-coinfected patients. Individuals included in the HEPAVIR-DAA (NCT02057003) cohort were selected if they had received all-oral DAA combinations. A retrospective review of clinical events registered between the start of DAAs and 12 months after SVR12 was carried out...
September 10, 2018: Journal of Viral Hepatitis
Serena Y C Lin, Brittany Rife Magalis, Marco Salemi, Hsin-Fu Liu
Hepatitis B virus disease progression in East Asia is most frequently associated with genotype C (HBV/C). The increasing availability of HBV/C genetic sequences and detailed annotations provides an opportunity to investigate the epidemiological factors underlying its evolutionary history. In this study, the Bayesian phylogeography framework was used to investigate the origins and patterns in spatial dissemination of HBV/C by analyzing East Asian sequences obtained from 1992 to 2010. The most recent common ancestor of HBV/C was traced back to the early 1900s in China, where it eventually diverged into two major lineages during the 1930s-1960s that gave rise to distinct epidemic waves spreading exponentially to other East Asian countries and the United States...
September 10, 2018: Journal of Viral Hepatitis
Hong Zhao
I read with interest the article by Liu and colleagues on the epidemiology of hepatitis B virus (HBV) infection in China.1 According to the data in the National Notifiable Communicable Disease Report System in China (NNCDRS), the authors concluded that older people (≥55 year-old) have increased HBV infection.1 However, I believe that the NNCDRS data were erroneously interpreted and the conclusion is misleading. This article is protected by copyright. All rights reserved.
September 10, 2018: Journal of Viral Hepatitis
Momoko Iwamoto, Aurelie Calzia, Amelie Dublineau, François Rouet, Janin Nouhin, Sokchea Yann, Sophorn Pin, Chhorvy Sun, Kimchamroeun Sann, Chhit Dimanche, Celine Lastrucci, Rebecca M Coulborn, David Maman, Jean-Philippe Dousset, Anne Loarec
GeneXpert® (Cepheid) is the only WHO prequalified platform for Hepatitis C Virus (HCV) Nucleic Acid Amplification Testing that is suitable for point-of-care use in resource-limited contexts. However, its application is constrained by the lack of evidence on genotype 6 (GT6) HCV. We evaluated its field performance among a patient population in Cambodia predominantly infected with GT6. Between August and September 2017, we tested plasma samples obtained from consenting patients at Médecins Sans Frontières' HCV clinic at Preah Kossamak Hospital for HCV viral load (VL) using GeneXpert® and compared its results to those obtained using COBAS® AmpliPrep/Cobas® TaqMan® HCV Quantitative Test, v2...
September 10, 2018: Journal of Viral Hepatitis
Francesco Paolo Bianchi, Maria Serena Gallone, Maria Filomena Gallone, Angela Maria Vittoria Larocca, Luigi Vimercati, Michele Quarto, Silvio Tafuri
According to international guidelines, healthcare workers and medical students immunized against HBV are periodically tested for anti-HBs IgG. Subjects who show an anti-HBs titer <10 mUI/ml must receive additional vaccine doses to induce a measurable antibody response. This study aimed to evaluate the long-time immunogenicity of anti-hepatitis B vaccination in a sample of medical students and residents of the University of Bari who attended the Hygiene Department for biological risk assessment (April 2014 - June 2017)...
September 10, 2018: Journal of Viral Hepatitis
Mary A Rodgers, Vera Holzmayer, Ana Vallari, Ana Olivo, Kenn Forberg, Jill Fuhrman, Kelly E Coller, Bih Awazi, Jules Bertrand Kenmegne Sidje, Matthew B Frankel, Michael G Berg, Dora Mbanya, Nicaise Ndembi, Gavin A Cloherty
The prevalence of chronic hepatitis C virus (HCV) and the presence of human pegivirus 2 (HPgV-2) have not been examined in Cameroon, although HCV has been associated with HPgV-2 infections previously. Herein we aimed to characterize the burden and genetic diversity of HCV and the presence of HPgV-2 in Cameroon. Retrospective plasma specimens collected from N=12,369 consenting subjects in South Cameroon from 2013 - 2016 were included in the study. The majority (97.1%) of participants were patients seeking healthcare...
September 5, 2018: Journal of Viral Hepatitis
Minh Cuong Duong, Mary-Louise McLaws
Selecting the appropriate screening method and interval for the early detection of hepatitis C virus (HCV) infection in low-resourced hemodialysis settings is a challenge. The challenge occurs when patients are classified as HCV-RNA positive but negative to HCV-core antigen (HCV-coreAg), anti-HCV and genotyping tests. We aim to clarify the inconsistency between HCV-RNA, HCV-coreAg, anti-HCV, and HCV genotyping tests in hemodialysis patients and determine the reliability of HCV-coreAg as a routine two-monthly screening strategy...
September 5, 2018: Journal of Viral Hepatitis
M J H van Campenhout, W P Brouwer, Q Xie, S Guo, H Chi, X Qi, F Tabak, A Streinu-Cercel, J-Y Wang, N Zhang, R Idilman, H W Reesink, M Diculescu, K Simon, M Akdogan, W Mazur, R J de Knegt, E Verhey, B E Hansen, H L A Janssen
Addition of peginterferon alpha (PEG-IFN add-on) to entecavir (ETV) treatment after a short lead-in phase results in more response than ETV monotherapy in HBeAg positive chronic hepatitis B infection (CHB). This study is the first to assess long-term efficacy of this treatment strategy. Patients who received ETV +/- 24 weeks of PEG-IFN add-on in a global trial (ARES study) and completed follow-up were eligible to participate in this observational LTFU study if they had at least one combined HBeAg and HBV DNA measurement beyond week 96 of the ARES study...
September 5, 2018: Journal of Viral Hepatitis
Sukriti Sukriti, Manish Chandra Choudhary, Jaswinder Singh Maras, Sachin Sharma, Swati Thangariyal, Avishek Singh, Sukanto Das, Mojahidul Islam, Shvetank Sharma, Nirupama Trehanpati, Ekta Gupta, Shiv Kumar Sarin
Hepatitis B virus persists in all patients with infection, even those with evidence of serological recovery. Patients with inactive or resolved HBV infection are at a high risk of HBV reactivation. Extracellular vesicles have been shown to serve as vehicles for intercellular communication and transfer of genetic material. We investigated whether extracellular vesicles carry infection and serve as reservoir of HBV DNA. EVs were isolated from chronic hepatitis B (CHB) patients, Group1: qHBsAg+ve with undetectable HBV DNA post-antiviral therapy [n=9]; Group 2: CHB with detectable HBV DNA>103 [n=12], compared with healthy controls (HC) (n=20)...
September 5, 2018: Journal of Viral Hepatitis
Hilde Vroling, Anouk M Oordt-Speets, Giordano Madeddu, Sergio Babudieri, Roberto Monarca, Eamonn O'Moore, Marije Vonk Noordegraaf-Schouten, Hans Wolff, Marialinda Montanari, Dagmar Hedrich, Lara Tavoschi
Hepatitis C prevalence in prison populations is much higher than in the community. Effective hepatitis C treatment within this population does not only have a direct individual health benefit, but may lead to substantial community dividend. We reviewed available evidence on hepatitis C treatment in prison settings, with a focus on the European Union/European Economic Area. A systematic review of the literature (Pubmed, Embase, Cochrane Library) was performed, and complemented with searches for conference abstracts and grey literature...
September 5, 2018: Journal of Viral Hepatitis
Henry Lik Yuen Chan, Fiona Wai Sze Chan, Aric Josun Hui, Michael Kin Kong Li, Kam Hon Chan, Grace Lai Hung Wong, Ching Kong Loo, Angel Mei Ling Chim, Chi Hang Tse, Vincent Wai Sun Wong
Nucleos(t)ide analogues (NA) are effective in suppressing hepatitis B virus (HBV) replication, but most patients require long-term treatment. This study aimed to investigate switching to peginterferon as a strategy to stop NA. Hepatitis B e antigen (HBeAg)-positive chronic hepatitis B patients who developed HBeAg seroconversion during NA treatment were studied. All patients received open-label peginterferon alfa-2a 180mcg/week for 48 weeks, and NA was stopped at week 4 of peginterferon treatment. The primary endpoint was sustained response, which was defined as negative HBeAg, positive anti-HBe and HBV DNA <2000 IU/ml at week 72...
September 5, 2018: Journal of Viral Hepatitis
Christoph Höner Zu Siederdissen, Benjamin Maasoumy, Markus Cornberg
The management of chronic hepatitis B virus (HBV) infection is challenged by its varying natural course and its stealthy nature. Not all HBV infected patients will develop complications of infection; however, it is of utmost importance to identify patients who are at risk and require antiviral treatment and/or close surveillance. Hepatic inflammation and quantification of HBV DNA have guided treatment decisions in the last decade and these guided interventions have been shown to reduce liver related complications and death...
September 5, 2018: Journal of Viral Hepatitis
Pietro Lampertico, Maurizia R Brunetto, Antonio Craxì, Giovanni B Gaeta, Mario Rizzetto, Antonella Rozzi, Massimo Colombo
Nucleos(t)ide analogues (NAs) and peginterferon have complementary effects in chronic hepatitis B, but it is unclear whether combination therapy improves responses in genotype D-infected patients. We conducted an open-label study of peginterferon alfa-2a 180 μg/week added to ongoing NA therapy in hepatitis B e antigen (HBeAg)-negative, genotype D-infected patients with HBV DNA <20 IU/mL. The primary endpoint was proportion of patients with ≥50% decline in serum HBsAg by the end of the 48-week add-on phase...
September 5, 2018: Journal of Viral Hepatitis
Lise Lafferty, Jake Rance, Jason Grebely, Andrew R Lloyd, Gregory J Dore, Carla Treloar
Hepatitis C virus (HCV) infection is a major public health concern. Globally, 15% of those incarcerated are HCV-antibody positive (anti-HCV). Even where HCV treatment is available within prisons, treatment uptake has remained low. This qualitative study was conducted to understand the barriers and facilitators for the delivery of HCV treatment in prisons from the perspectives of prisoners. This is important to inform health messaging for HCV treatment within correctional institutions. Thirty-two prisoners (including eight women) with a history of injecting drug use participated in this qualitative study...
August 23, 2018: Journal of Viral Hepatitis
Elena Perpiñán, Noelia Caro-Pérez, Neris García-González, Josep Gregori, Patricia González, Concepción Bartres, Maria Eugenia Soria, Celia Perales, Sabela Lens, Zoe Mariño, María Carlota Londoño, Xavier Ariza, George Koutsoudakis, Josep Quer, Fernando González-Candelas, Xavier Forns, Sofía Pérez-Del-Pulgar
AIM: The emergence of resistance-associated substitutions (RASs) can compromise the high efficacy of direct-acting antivirals (DAAs). Little is known about RASs selection at very early time points during DAA treatment. Therefore, we analyzed the potential emergence of RASs immediately after therapy initiation. MATERIALS AND METHODS: Samples of 71 patients treated with different DAAs were collected at baseline, during therapy (hours 4 and 8; days 1-7; weeks 2-4) or until target-not-detected...
August 23, 2018: Journal of Viral Hepatitis
Sahar Saeed, Erica Em Moodie, Erin Strumpf, John Gill, Alexander Wong, Curtis Cooper, Sharon Walmsley, Mark Hull, Valerie Martel-Laferriere, Marina B Klein
Clinical trial results of direct acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) have shown improvements in health-related quality of life (HR-QoL). However, the extent to which these results are broadly generalizable to real-world settings is unknown. We investigated the real-world impact of oral DAA therapy on HR-QoL among individuals co-infected with HIV/HCV. We used data from the Canadian HIV/HCV Co-Infection Cohort Study that prospectively follows 1795 participants from 18 centers...
August 23, 2018: Journal of Viral Hepatitis
Hannah Jones, Priyanka Patel, Dawn Sears
In 2013, the United States Preventative Services Task Force released a recommendation that patients born between 1945 and 1965 (baby boomers) be screened for Hepatitis C virus antibody (anti-HCV). To increase Hepatitis C screening, treatment, and number of cures for the baby boomer population at Scott & White Medical Center-Temple in Central Texas through Electronic Medical Record (EMR) reminders, an Institutional Review Board-approved prospective study comparing hepatitis C screening one year before and one year after EMR reminder activation was performed...
August 23, 2018: Journal of Viral Hepatitis
Juan Macías, Rafael Granados, Francisco Téllez, Dolores Merino, Montserrat Pérez, Luis E Morano, Rosario Palacios, María Paniagua, Mario Frías, Nicolás Merchante, Juan A Pineda
Among patients with cirrhosis, recovery of liver function after SVR to all-oral direct acting antivirals (DAA) in HIV/HCV coinfection could be different to that in HCV monoinfection. Because of this, we compared the changes in several markers of liver function between HCV-monoinfected and HIV/HCV-coinfected patients with cirrhosis who achieved SVR12 to DAA combinations. In this retrospective cohort study, cirrhotics included in the HEPAVIR-DAA and GEHEP-MONO cohorts were selected if they had SVR12 to all-oral DAAs...
August 23, 2018: Journal of Viral Hepatitis
Seng Gee Lim, Wah Wah Phyo, Samir R Shah, Khin Maung Win, Saeed Hamid, Teerha Piratvisuth, Soek Siam Tan, Yock Young Dan, Yin Mei Lee, Taufique Ahmed, Wei Lyn Yang, Kok Pun Chen, Mrunal Kamat, Manav Wadhawan, Kaushal Madan, Rajiv Mehta, Akash Shukla, Prashant Dhore, C E Eapen, Priya Abraham, Satyendra Tyagi, Abraham Koshy, Aung Hlaing Bwa, Wasim Jafri, Shahab Abid, Fakhar Ali Qazi Arisar, Tewesak Tanwandee, Thing Phee Yin, Hoi Poh Tee, Rosaida Binti Hj Md Said, Khean Lee Goh, Shiaw Hooi Ho, Rosmawati Mohamed, Norasiah Abu Bakar
There is a paucity of information on Chronic Hepatitis C (CHC) patients treated with direct antiviral agents (DAA) in Asia. We invited Asia-Pacific physicians to collate databases of patients enrolled for CHC treatment, recording baseline clinical, virological and biochemical characteristics, sustained virological response at week 12 (SVR12), and virologic failure. SVR12 outcome was based on intention-to-treat (ITT). Multivariate analysis was used to assess independent risk factors for SVR12 using SPSS version 20...
August 23, 2018: Journal of Viral Hepatitis
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"